Κλείστε το ραντεβού σας

Βιογραφικό

Αρχική > Βιογραφικό

Γεώργιος Νίντος MD ΜSc
Παθολόγος- Ογκολόγος

Εκπαίδευση

ΕΙΔΙΚΕΥΣΗ ΣΤΗΝ ΠΑΘΟΛΟΓΙΚΗ ΟΓΚΟΛΟΓΙΑ | 2016 | ΠΑΝΕΠΙΣΤΗΜΙΑΚΟ ΝΟΣΟΚΟΜΕΙΟ ΗΡΑΚΛΕΙΟΥ, ΚΡΗΤΗ

ΠΤΥΧΙΟ ΙΑΤΡΙΚΗΣ | 2006 | ΙΑΤΡΙΚΗ ΣΧΟΛΗ, ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΑΣ
• ‘Άριστα’

MSC ΣΤΗΝ ΟΓΚΟΛΟΓΙΑ ΘΩΡΑΚΟΣ | 2014 | ΙΑΤΡΙΚΗ ΣΧΟΛΗ, ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΑΣ
• ‘Άριστα’

Επαγγελματική εμπειρία

block

ΑΠΡ 2025- ΣΗΜΕΡΑ: ΓΕΝΙΚΗ ΚΛΙΝΙΚΗ ΙΑΣΩ, ΑΘΗΝΑ

  • Ειδικός Συνεργάτης Παθολογικής Ογκολογίας
block

ΝΟΕ 2023 – ΣΗΜΕΡΑ: CITY HOSPITAL, ΚΑΛΑΜΑΤΑ

  • Ειδικός Συνεργάτης Παθολογικής Ογκολογίας
block

ΟΚΤ 2022 – ΣΗΜΕΡΑ: ΘΕΡΑΠΕΥΤΗΡΙΟ ΥΓΕΙΑ KAI ΓΕΝΙΚΟ ΝΟΣΚΟΜΕΙΟ ΜΗΤΕΡΑ, ΑΘΗΝΑ

  •  Επιμελητής Παθολογικής Ογκολογίας, Ε’ Παθολογική- Ογκολογική Κλινική
block

ΝΟΕ 2020 – ΑΠΡ 2022: NORTH MIDDLESEX UNIVERSITY HOSPITAL, ΛΟΝΔΙΝΟ

  •  Consultant in Medical Oncology for Thoracic and Breast Cancer
block

NOΕ 2019 – ΟΚΤ 2021: KING’S COLLEGE LONDON, ΛΟΝΔΙΝΟ

  • Senior Clinical Research Fellow, Honorary Contract, King’s College London (Assistant Professor Sophie Papa)
block

ΙΟΥΛ 2018 – ΟΚΤ 2021: GUY’S AND ST THOMAS’ NHS FOUNDATION TRUST, ΛΟΝΔΙΝΟ

  • Senior Clinical Research Fellow, Department of Experimental Cancer Medicine (Professor James Spicer)
block

ΑΠΡ 2016 – ΙΟΥΛ 2018: NORTH MIDDLESEX UNIVERSITY HOSPITAL, ΛΟΝΔΙΝΟ

  • Specialist Registrar in Medical Oncology, Department of Medical Oncology
block

IAN 2013 – ΔΕΚ 2015: ΠΑΝΕΠΙΣΤΗΜΙΑΚΟ ΝΟΣΟΚΟΜΕΙΟ ΗΡΑΚΛΕΙΟΥ, ΚΡΗΤΗ

  • Ειδίκευση στην Παθολογική Ογκολογία, Πανεπιστημιακό Νοσοκομείο Ηρακλείου, Κρήτη
block

MAΡ 2010 – ΣΕΠΤ 2012: ΝΟΣΟΚΟΜΕΙΟ ΝΟΣΗΜΑΤΩΝ ΘΩΡΑΚΟΣ ‘ΣΩΤΗΡΙΑ’, ΑΘΗΝΑ

  • Ειδίκευση στην Γενική Παθολογία και Αιματολογία
block

ΜΑΙ 2008 – ΙΟΥΛ 2009: ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΠΥΡΓΟΥ, ΗΛΕΙΑ

  • Υπηρεσία υπαίθρου
block

ΑΥΓ 2006 – ΑΥΓ 2007

  • Στρατιωτική θητεία, υπηρεσία ως στρατιωτικός ιατρός
Ερευνητική εμπειρία

• Κατά την παραμονή του στο Ηνωμένο Βασίλειο (Guy’s Hospital, King’s College London, North Middlesex University Hospital) – παράλληλα με την κλινική του δραστηριότητα – επι-κέντρωση σε ογκολογικές μελέτες σχετιζόμενες κυρίως με την ασφάλεια και αποτελεσματικότητα νέων κατηγοριών θεραπείας (first-in-human μελέτες) και κυτταρικές θεραπείες. Ενδεικτικά, συμμετοχή σε:
o Phase 1 trial of Mov18, a first-in-class IgE antibody therapy for cancer
o Blu-667, phase 2 study of the highly selective RET inhibitor in patients with thyroid cancer, non-small cell lung cancer and other advanced solid tumors
o μελέτη για την ασφάλεια και την αποτελεσματικότητα TILs (tumor infiltrating lymphocytes (TIL; LN-145) για προχωρημένο, υποτροπιάζων ή μεταστατικό καρκίνο κεφαλής/τραχήλου σε συνδυασμό με pembrolizumab (Guy’s Hospital)
o RXC004/001: A phase I/II study to evaluate the safety and tolerability of RXC004, a Wnt pathway inhibitor, alone and in combination with anti-cancer treatments in pa-tients with advanced malignancies.
o T4 immunotherapy: phase I trial for head and neck cancer
o ADAPTIMMUNE (ADP-0033-001): phase I trial evaluating safety and anti-tumor activity of autologous T cells expressing Afpc332t in Hla-A2 positive subjects with advanced hepatocellular carcinoma
• Sequential administration of vinorelbine plus cisplatin and bevacizumab (VCB) followed by docetaxel plus gemcitabine and bevacizumab (DGB) compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous NSCLC: A multicenter randomized phase II trial (Νοέμβριος 2014) – συμμετοχή στη διαλογή και παρακολούθηση ασθενών και πρωτογενή συλλογή δεδομένων
• Retrospective study of skeletal-related events in a cohort of lung cancer patients (research project realized for MSc dissertation in Thoracic Oncology) (Ιούλιος 2014) – σχεδιασμός μελέτης, ανασκόπηση βιβλιογραφίας, συλλογή δεδομένων και στατιστική ανάλυση
• Συλλογή και ηλεκτρονική αρχειοθέτηση δεδομένων του Πανελλήνιου Μητρώου Κακοηθειών Εγκεφάλου (συνεργασία Πανεπιστημιακού Νοσοκομείου Ηρακλείου και Τμήματος Επιδημιολογίας, Πανεπιστήμιο Αθήνας)
• Συλλογή και ηλεκτρονική αρχειοθέτηση πρωτογενών δεδομένων σε μελέτη του οικογενειακού ιστορικού κακοήθειας σε πληθυσμό ασθενών με καρκίνο μαστού, Πανεπιστημιακό Νοσοκομείο Ηρακλείου
• Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous NSCLC: a multi-center phase II study of the Hellenic Oncology Research Group (Φεβρουάριος 2014) – participation in patient recruitment, screening process, monitoring and primary data collection
• Meta-analysis of two irinotecan-based phase III randomized trials for the efficacy and treatment tolerance in older patients with metastatic colorectal cancer (Ιούνιος 2013) – participation in literature review and data entry

• Post EAU/ASCO bladder cancer workshop: implementing new data, Guy’s Hospital, June 26, 2019
• New Technologies in Thoracic Oncology Conference, June 24, 2019, Guy’s Hospital
• Good Clinical Practice – refresher course, February 13, 2019
• British Thoracic Oncology Group Meeting, Dublin, Ireland, January 23-25, 2019
• Advanced Life Support, North Middlesex University Hospital, June 3, 2018
• Leadership and Management course for doctors, Oxford Medical, London, January 8-10, 2018
• Advanced Communication Skills Course for Doctors, Oxford Medical, London, December 4-5, 2017
• Early access to Medicines Scheme (EAMS) NSCLC Pembrolizumab Training, North Middlesex, 2017
• Chemotherapy Competency Module, North Middlesex University Hospital NHS Trust, 2016

  • 1347-201 FUZE trial EU Investigator Meeting, Budapest, Hungary, April 11, 2019
  • MK 7902-005 Investigator Meeting, Paris, February 21-22, 2019
  • European Lung Cancer Congress, Γενεύη, Απρίλιος 11-14, 2018
  • ESMO Sarcoma and GIST Symposium, Μιλάνο, Φεβρουάριος 5-7, 2018
  • Best of World Conference on Lung Cancer by the Hellenic Oncology Research Group, Αθήνα, Φεβρουάριος 28 – Μάρτιος 1, 2014
  • Masterclass on circulating tumors cells and molecular biomarkers – Hellenic Oncology Research Group (HORG)’, Κρήτη, Δεκέμβριος 15-17, 2014
  • 4th Educational Seminar of the Hellenic Oncology Academy: Malignant Neoplasms of Uropoietic System, Αθήνα, Νοέμβριος 28-30, 2014
  • 3rd Educational Seminar of the Hellenic Oncology Academy: malignant neoplasms of the Gastrointestinal system, Αθήνα, Οκτώβριος 3-5, 2014
  • 2nd Educational Seminar of the Hellenic Oncology Academy: Malignant Neoplasms of the Thorax, Mediastinum, Head and Neck, Αθήνα, Μάιος 23-24, 2014
  • Preceptorship in Clinical and Translational Cancer Research – Integrated management of cancer patients, Κρήτη, Ιανουάριος 27-30, 2014
  • Young Oncologists Group Seminar ‘Cancer Pharmacogenetics and Pharmacogenomics as tools for Clinical Practice and Research’, Αθήνα, Νοέμβριος 16, 2013
  • Best of ASCO – Annual Meeting 2013’, Hellenic Oncology Research Group, Σεπτέμβτιος 20-21, 2013
  • 15ο Πανελλήνιο Αιματολογικό Συνέδριο, Αθήνα, Νοέμβριος 24-28, 2012
  • 2nd Lung Cancer Network ‘From the bench to the bedside, Αθήνα, Φεβρουάριος 2-4, 2012
  • 5th Oncology Congress of Oncology in Primary Care, Woman and cancer, Αθήνα, Δεκέμβριος 1-3, 2011
  • 4th Oncology Congress of Oncology in Primary Care, Domiciliary cancer care, Αθήνα, Δεκέμβριος 3-4, 2010
  1. Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, Jones GN, Willis SE, Petrone M, Silva C, Thway K, Bunce C, Roxanis I, Nenclares P, Wilkins A, McLaughlin M, Jayme-Laiche A, Benafif S, Nintos G, Kwatra V, Grove L, Mansfield D, Proszek P, Martin P, Moore L, Swales KE, Banerji U, Saunders MP, Spicer J, Forster MD, Harrington KJ. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024 Jan 16;134(2):e175369
  2. Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, Selkirk C, Nintos G, Kwatra V, Funingana IG, Doherty G, Gould HJ, Pellizzari G, Nakamura M, Ilieva KM, Khiabany A, Stavraka C, Chauhan J, Gillett C, Pinder S, Bax HJ, Josephs DH,Karagiannis SN. Safety and anti-tumour activity of the IgE antibody Mov18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nat Commun. 2023 Jul 25;14(1):4180. doi: 10.1038/s41467-023-39679-9.
  3. Syrios, G. Nintos, V. Georgoulias. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small cell lung cancer. Expert Review of Anticancer Therapy Journal 2015;15 (8): 875-84
  4. Koinis, G. Nintos (first authors), A. Kotsakis, V. Georgoulias. Therapeutic strategies for chemotherapy induced neutropenia. Expert Opinion on Pharmacotherapy Journal 2016;16 (10): 1-15
  5. Matikas, E. Kontopodis, G. Nintos, T. Bilidas, D. Kofteridis, E. Papadaki, E. Lyraraki, K. Kanatsouli, D. ‘Α case of Herpes Simplex encephalitis after brain irradiation for lung cancer metastases’ Anticancer Res 2014;34: 4411-14
  6. Kotsakis, N. Kentepozidis, C. Emmanouilidis, A. Polyzos, A. Agelidou, M. Vaslamatzis V. Chandrinos, S. Aggelaki, L. Vamvakas, K. Kalbakis, P. Katsaounis, D. Stoltidis, G. Nintos, D. Hatzidaki, D. Mavroudis, V. Georgoulias, on behalf of the Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), Athens, Greece. Sequential administration of Vinorelbine plus Cisplatin and Bevacizumab followed by Docetaxel plus Gemcitabine and Bevacizumab compared to Docetaxel plus Cisplatin and Bevacizumab regimen as First-line therapy for advanced or metastatic non- squamous Non-Small Cell Lung Cancer: A multicenter randomized Phase II trial of the Hellenic Oncology Research Group (HORG). Lung Cancer 2015 Jan 23

 

  • Nintos, E. Saloustros, A. Margiolaki, V. Georgoulias, D. Mavroudis. Study of cancer family history documentation in breast cancer patients. Need for a more complete and better-quality documentation, 21st Panhellenic Congress in Medical Oncology, April 23-25, 2015, Athens
  • Mala, E. Saloustros, G. Nintos, K. Kalbakis, N. Androulakis, S. Aggelaki, L. Vamvakas, N. Vardakis, C. Kourousis, A. Margiolaki, T. Skaltsi, V. Georgoulias, D. Mavroudis. A decreased acceptability of breast mammogram screening is associated with more advanced stage at diagnosis and higher mastectomy rates. 21st Panhellenic Congress in Medical Oncology, April 23-25, 2015, Athens
  • Kentepozidis, A. Kotsakis, C. Nikolaou, G. Nintos, A. Soultati, S. Aggelaki, C. Christophyllakis, M. Agelidou, L. Vamvakas, V. Georgoulias. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG), 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, October 9-11, 2014, Athens
  • Matikas, A. Karampeazis, S. Aggelaki, N. Kentepozidis, A. Kotsakis, E. Kontopodis, C. Christophyllakis, C. Nikolaou, G. Nintos, V. Georgoulias, L. Vamvakas. Carboplatin and gemcitabine as first-line treatment in NSCLC elderly patients: first results of a multi-center phase II study, 2nd Panhellenic Congress of Medical Oncology, April 10-12, 2014, Thessaloniki
  • N. Kentepozidis, A. Kotsakis, C. Nikolaou, Nintos, A. Soultati, S. Aggelaki, C. Christophyllakis, M. Agelidou, L. Vamvakas, V. Georgoulias. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous NSCLC: a multicenter phase II study of the Hellenic Oncology Research Group. ICACT 2014, 25th International Congress on Anti-Cancer Treatment, February 4-6, 2014, Paris
  • Vamvakas, A. Karampeazis, I. Boukovinas, S. Kakolyris, A. Polyzos A., G. Nintos, T. Bilidas, M. Stratigos, V. Georgoulias, J. Souglakos and the Hellenic Oncology Research Group (HORG). A meta-analysis of two irinotecan-based phase III randomized trials for the efficacy and treatment tolerance in older patients with metastatic colorectal cancer (MCRC). 13th Conference of the International Society of Geriatric Oncology (SIOG) (Journal of Geriatric Oncology 2013;4 (suppl 1): p.52), October 2013, Copenhagen
  • Skeletal-related events in Lung Cancer, 5th Oncology Congress, Primary care, Women and Cancer, December 2011, Athens
  • Hepatic abscess: interesting clinical case presentation, 20th Internal Medicine Days, April 2011, Athens
  • Experience of next generation somatic mutation testing in advanced breast cancer at Guy’s Cancer Centre. Tong D, Nintos G, Sarker D, Mansi J, Sawyer E.

ONCOLOGY DEPARTMENT | NORTH MIDDLESEX UNIVERSITY HOSPITAL | 2018
• ‘Comparison of 5 versus 10-day course of GCSF for breast cancer patients as primary prophylaxis for the prevention of neutropenic sepsis’
• Audit aimed at improving prevention of neutropenic sepsis for patients routinely treated on the Oncology ward with chemotherapy
GUY’S CANCER CENTRE| GUYS AND ST THOMAS’ FOUNDATION TRUST | 2019
• Quality assessment for Foundation Medicine project in cancer patients enrolled in year 2018
• Audit aimed at improving cancer treatment protocols based on genetic alterations results from previous years
GUY’S CANCER CENTRE| GUYS AND ST THOMAS’ FOUNDATION TRUST | 2019
• Review of SCLC cancer patient treatment results 2013-2017
• Audit aimed at comparing treatment and survival rates with 2018 results

 

Είπαν για εμάς

Γεώργιος Νίντος
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.